Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study aims to evaluate the safety and mechanisms of action of the trimodality treatment (radiotherapy, immunotherapy and surgery) in early-stage non-small cell lung cancer. Half of the patients will receive stereotactic ablative radiotherapy followed by 2 cycles of immunotherapy (pembrolizumab); the other half will not receive the immunotherapy treatment. After treatment, both groups will continue treatment according to guidelines and will undergo surgery (lobectomy).
Epistemonikos ID: 4b84e96eba75eaafbe0fd9b0e8ec450e4230910e
First added on: May 21, 2024